Peripheral blood lymphocytes (PBLs) 
ability of amphotropic and pseudotyped vectors expressing a murine cell surface protein, B7-1, to infect the human T-cell line Jurkat or human blood lymphocytes. Limiting dilution analysis of transduced Jurkat cells demonstrated that the pseudotyped vector is significantly more efficient in infecting T cells than an amphotropic vector used at the same multiplicity of infection (moi). To identify the transduction efficiency on PBLs, we examined the levels of cell surface expression of the B7-1 surface marker 48 to 72 hr after infection. The transduction efficiency ofPBLs with the pseudotyped vector increased linearly with increasing moi to a maximum of approximately 16-32% at an moi of 40. This relatively high efficiency of infection of a T-cell line and of blood lymphocytes with VSV-G pseudotyped virus demonstrates that such modified pseudotyped retrovirus vectors may be useful reagents for studies of gene therapy for a variety of genetic or neoplastic disorders.
T lymphocytes are relatively long-lived (1) cells of the hematopoietic system that regulate immune responses to infectious or neoplastic disease. T-cell function is impaired in a variety of genetic or acquired diseases that affect lymphocytes, resulting in immunodeficiency, severe chronic infections, or neoplasia. Since most circulating lymphocytes are T cells, the peripheral blood lymphocyte compartment is an important target for genetic modification. Unfortunately, T cells are refractory to most current viral and non-viral gene transfer techniques. Only retrovirus vectors have been found useful in transferring foreign, potentially therapeutic genes into a variety of lymphocytes in vitro, including peripheral blood lymphocytes (PBLs) and tumor-infiltrating lymphocytes (2) (3) (4) (5) (6) (7) (8) . This has led to several clinical gene therapy studies involving gene transfer into such cells (6) (7) (8) (9) (10) (11) .
The recent results with adenosine deaminase deficiency (ADA) reconstitution studies demonstrated that a limited degree of gene transfer and prolonged gene MATERIALS AND METHODS Plasmids. The cDNA encoding the murine immune accessory molecule B7-1 (muB7) cDNA, a gift from James Allison (University of California, Berkeley), was subcloned into pBluescript polylinker. A HindIII-XbaI fragment with the muB7 cDNA was then blunt-ended and inserted into the blunt-ended BamHI site of vector plasmid pLPONL (16) , which expresses the neomycin phosphotransferase gene from the Moloney retroviral 5' long terminal repeat by virtue of the presence of a poliovirus ribosome reentry sequence (PO). The resulting plasmid was designated pLPONL-muB7.
Retrovirus Vector Preparation. Vector pLPONL-muB7 plasmid DNA was transfected into the packaging cell line PA317 (17) by -using the established calcium phosphate transfection method (18) . Forty-eight hours after transfection, the culture medium containing amphotropic LPONL-muB7 virus was used to infect 293GP cells, which express high levels of Moloney murine leukemia virus gag and pol (12) . After Abbreviations: PBL, peripheral blood lymphocyte; VSV-G, G glycoprotein of vesicular stomatitis virus; moi, multiplicity of infection; muB7, murine immune accessory molecule B7-1; IL-2, interleukin 2; FACS, fluorescence-activated cell sorter; PE, phycoerythrin; FITC, fluorescein isothiocyanate; TE, transduction efficiency. tTo whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. selection in G418-containing medium (400 ,tg/ml) for 2 weeks, colonies were picked and the clones (muB7/293GP cells) expressing high levels of the muB7 transgene, as assessed by flow cytometric analysis (see below), were pooled.
The preparation of high-titer VSV-G-pseudotyped LPONLmuB7 vector was carried out by methods described previously (13) . The muB7/293GP cells were transfected with plasmid pHCMV-G expressing VSV-G from the human cytomegalovirus (HCMV) promoter (13) by using the calcium phosphate method. Culture media were collected at 48 and 72 hr after transfection, filtered through a 0.45-,um pore diameter filter, and concentrated by ultracentrifugation as described (13) . Virus was titered on 208F cells by infection with virus dilutions in the presence of Polybrene (8 ,ug/ml) followed by G418 selection (400 ,g/ml) starting 24 hr after infection. G418-resistant colonies were counted 10-12 days after infection. Aliquots of virus stocks were frozen at -70°C. To obtain retrovirus enveloped with an amphotropic envelope, plasmid pHCMV-ampho-env was constructed by excising the BamHI fragment VSV-G cDNA from pHCMV-G and replacing it with a 2.8-kb EagI fragment from plasmid PA14 (from A. Rein, National Cancer Institute-Frederick Cancer Research and Development Center) containing the complete amphotropic envelope gene. Plasmid pHCMV-ampho-env was also transfected into muB7/293GP cells and culture medium was collected 48 hr thereafter, filtered through a 0.45-,um filter, and stored at -70°C. The amphotropic virus was also titered by infecting rat 208F cells, as described above.
Cell Lines and Primary Lymphocytes. Jurkat cells were grown in complete medium [RPMI medium 1640 with 10% fetal bovine serum and 10 mM Hepes (Sigma)], at 37°C in a 5% CO2 incubator. Human PBLs were isolated from the buffy coat of donors by Ficoll-Hypaque gradient centrifugation (Histopaque 1077, Sigma). PBLs were cultured in complete medium supplemented with human recombinant interleukin 2 (IL-2; Sigma) at 100 units/ml. An enrichment column for CD4+ cells (R & D Systems) was used to isolate human CD4+ cells from PBLs by methods specified by the manufacturer.
Infection of the Jurkat T-Cell Line. A total of 5 x 105 Jurkat cells in complete medium were plated into 6-well plates in a total volume of 2 ml of medium per well. Twenty-four hours after plating, the cells were infected by addition of amphotropic or VSV-G-pseudotyped LPONL-muB7 vector in the presence of Polybrene at a final concentration of 8 ,ug/ml. Under these conditions, the TE of the amphotropic virus was 0.6% + 0.1%. In contrast, the pseudotyped vector had a TE of 11.95% + 0.6%, a 22-fold difference.
Because of its high titer, we were able to infect Jurkat cells with the pseudotyped vector at higher moi values than was possible with the amphotropic vector. We carried out the infection at an moi of 2, 10, 20, or 50 with the pseudotyped retrovirus LPONL-muB7. The experiment was performed three times, and Fig. 1 illustrates the percentage of cells expressing the muB7 marker as a function of moi. The percentage of Jurkat cells expressing the muB7 transgene increased linearly with respect to moi. At an moi of 2, muB7 marker was expressed on 2% of cells, and expression reached a mean maximum of 18% at an moi of 50. We did not examine mois greater than 50.
To determine the stability of transgene expression, we infected Jurkat cells with pseudotyped LPONL-muB7 at an moi of 20 and analyzed the muB7 expression at various times after infection. Transgene expression was detected at an early (36-hr) time point and persisted throughout the study period of 11 days, with 20-38% of Jurkat cells expressing the trans- (Fig. 2) . The percentage of cells expressing the muB7 transgene 48 hr after infection increased linearly with increasing moi, reaching a maximum of 25-30% at an moi of 40 (Table 2 and Fig. 3) . 10-20% (4, 5) . However, quantitative studies using FACS analysis to detect expression of the transgene product have reported efficiencies of only 1% per infection cycle (5). Higher estimates have been derived from nonquantitative experiments (4), while still others have been obtained from studies that required the use of extremely sensitive PCR methods to detect the presence, but not the expression, of vector sequences (21) . In a recent report, a retroviral vector containing the gibbon leukemia virus envelope glycoprotein instead of the Moloney leukemia virus counterpart was found to infect peripheral blood lymphocytes from human and nonhuman primate sources, particularly under conditions of phosphate depletion of the medium (21) .
A recent report (22) indicates that the infection efficiency with retroviruses in general is dependent on the concentration of retrovirus particles rather than on the moi per se, consistent with the high efficiency of infection in our study at an moi of A 40. In the present study, we demonstrate that the increased infection frequency in T cells of the VSV-G pseudotyped vectors compared with amphotropic vectors is likely to stem from two independent factors. The first involves the much higher titers and therefore the higher mois that are possible with the pseudotyped vectors compared with traditional amphotropic vectors that make possible the exposure of target cells to higher concentrations of vector. VSV-G-pseudotyped retrovirus vectors can be concentrated to titers in the range of 109 colony-forming units/ml because of the stability of the VSV-G-containing enveloped virus particles to centrifugal forces, in contrast to the marked instability of traditional amphotropic retrovirus vectors to such conditions. The second factor is the different and apparently more efficient mechanism of virus entry into exposed cells of the VSV-G pseudotyped vectors cell surface and seems to be related to other, more abundant, and possibly more readily exposed components of the cells' lipid bilayer. A comparison of the transduction efficiency of the pseudotyped vector with that of the amphotropic retroviral vector at equal mois of 1 indicates that the VSV-G virus is markedly better able to infect Jurkat cells.
We have used two independent methods to estimate the transduction efficiency of lymphocytes with pseudotyped retrovirus vectors: a limiting dilution assay to detect G418-resistant colonies and a FACS analysis of muB7 expression. Interestingly, the FACS analysis fails to detect transduced Jurkat cells at an moi of 2, while the limiting dilution assay indicates that an moi of 1 provides an infection efficiency of 12% (Fig. 1, Table 1 ). This discrepancy may be due to the relative insensitivity of the FACS assay or the expression level(s) of the different reporter genes, underscoring the difficulties of comparing infection frequencies in studies using different detection methods and different vectors. Nevertheless, the FACS assay of transgene expression provides a rapid measurement of the efficiency of infection and has advantages over Southern blot analysis or semiquantitative PCR (4, 6, 7, 21) , both of which provide information only on the presence, not on the expression, of the transgene in the infected cells. Furthermore, cells in Southern assays must be grown to sufficient numbers for DNA isolation, thereby allowing time for selection of subpopulations of cells with growth advantages and thereby possibly leading to errors in the estimation of initial transduction efficiency.
Although a direct comparison of the optimum conditions for T-cell infection with amphotropic virus and with the pseudotyped virus would be desirable, it has not been technically feasible under the conditions of our experiments. The low titer of amphotropic vectors prevents infection of cells at the very high mois that are achievable with the pseudotyped vectors, and the addition of large volumes of amphotropic vector to increase apparent mois would not allow high concentrations of vector to come into intimate enough contact with the target cells to allow infection. In addition, quantitative estimates of infection efficiency by FACS analysis under the conditions of these studies requires mois of greater than 2, as indicated by our finding that infection of Jurkat cells at an moi of 2 results in detectable expression of muB7 in only 2% of cells. Titers of amphotropic vectors sufficiently high to take advantage of the linear dose response of infection efficiency in T lymphocytes or CD4+ T cells (Fig. 2) are generally not possible.
Because of markedly different conditions for cell preparation and the use of different and often nonquantitative methods for determining infection, it is not possible to provide accurate quantitative comparisons of T-cell transductions reported in earlier studies with those of the present study. In our study, the infection efficiency of PBLs has been determined by a quantitative method for detecting expressed transgenes, and the efficiencies have ranged up to 16-32% after single cycles of infection. What is clear, furthermore, from the present work is that VSV-G-pseudotyped retrovirus vectors do permit much more efficient infection of T cells than is possible with identical vectors in an amphotropic envelope. The precise mechanisms responsible for enhanced infection of lymphocytes with the pseudotyped retrovirus vectors are not entirely clear. Virus titers determined on one cell type might not be entirely relevant to effective titers on another target cell type, since the availability of appropriate retrovirus receptors or phosphatidylserine or other VSV-G receptors may be entirely different in the different cell types. In the case of primary hepatocytes, which we know to be more readily infected with pseudotyped vectors than with traditional Moloney virus-based vectors, the enhanced infection is not associated with increased copy number of integrated viral genomes. We suspect that, in that case, the increased transgene expression from the pseudotyped vector results from increased numbers of cells being infected.
Since the eventual aim of all gene transfer studies is efficiency of both gene transfer and gene expression, the results described in the present study represent a useful and realistic quantitative assessment of both these parameters in lymphocytes transduced with pseudotyped retrovirus vectors.
Our data also provide evidence that the subset of CD45RO+ T cells is also susceptible to infection with VSV-Gpseudotyped retrovirus vectors. In a recent report, mature human T-cell preparations containing equal numbers of memory (CD45RO+) T cells and virgin or naive T cells (CD45RA+) were injected into severe combined immunodeficient (SCID) mice (20) . When these SCID mice were analyzed for the phenotype of the populating human T cells, only the memory (CD45RO+) T cells were detected, indicating that this phenotype is involved in long-term in vivo repopulation of hosts. Since our studies show that these cells are susceptible to retrovirus infection, it becomes possible to examine the effect of genetic modification of these cells on reconstitution studies in the SCID mouse model.
Obviously, many cell biology aspects of lymphocyte reconstitution in gene therapy studies in humans still need to be identified and solved. Nevertheless, we propose that some issues related to poor initial infection efficiency in lymphocytes may begin to be resolved through the use of modified retrovirus vectors, such as the VSV-G pseudotyped vectors, that permit increased efficiency of infection, thereby making it easier to develop new approaches to gene therapy of some genetic deficiency disorders and of acquired defects of T cells.
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